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Abstract
Overexpression of epidermal growth factor receptor (EGFR) is associated with many types of cancers. It is of great
interest to noninvasively image the EGFR expression in vivo. In this study, we labeled an EGFR-specific Affibody
molecule (Eaff) with a near-infrared (NIR) dye IRDye800CW maleimide and tested the binding of this labeled mole-
cule (Eaff800) in cell culture and xenograft mouse tumor models. Unlike EGF, Eaff did not activate the EGFR sig-
naling pathway. Results showed that Eaff800 was bound and taken up specifically by EGFR-overexpressing A431
cells. When Eaff800 was intravenously injected into nude mice bearing A431 xenograft tumors, the tumor could be
identified 1 hour after injection and it became most prominent after 1 day. Images of dissected tissue sections
demonstrated that the accumulation of Eaff800 was highest in the liver, followed by the tumor and kidney. More-
over, in combination with a human EGFR type 2 (HER2)–specific probe Haff682, Eaff800 could be used to distin-
guish between EGFR- and HER2-overexpressing tumors. Interestingly, the organ distribution pattern and the
clearance rate of Eaff800 were different from those of Haff682. In conclusion, Eaff molecule labeled with a NIR
fluorophore is a promising molecular imaging agent for EGFR-overexpressing tumors.
Neoplasia (2010) 12, 139–149
Introduction
The epidermal growth factor (EGF) receptor (EGFR, HER1, ErbB1)
is a transmembrane protein of the tyrosine kinase receptor family.
EGFR, together with human EGF receptor type 2 (HER2/ErbB2),
HER3/ErbB3, and HER4/ErbB4, makes up the ErbB family of type 1
tyrosine kinases. EGFR protein contains an extracellular ligand-binding
domain, a hydrophobic transmembrane domain, and an intracellular
domain with tyrosine kinase activity [1,2]. EGFR plays an important
role in physiological and pathological processes such as cell cycle pro-
gression, differentiation, apoptosis, migration, and invasion. Aberrant
overexpression and/or activation of EGFR is associated with many
types of cancers, including skin, breast, ovary, bladder, prostate, kidney,
head and neck, and non–small cell lung cancers [2,3]. Various EGFR-
targeted anticancer medicines have been developed by either targeting
the extracellular ligand-binding domain through antibody blocking, or
by inhibiting the tyrosine kinase activity using low–molecular weight
molecules [4,5].
To assess the expression level of EGFR in vivo, noninvasive imaging
methods have been developed. Most molecular imaging studies on
EGFR exploited the specific binding between the receptor molecule
and the anti-EGFR antibody. Successful imaging was achieved in both
small animal tumor models [6–9] and human patients [10,11]. How-
ever, because of their large size (Mw, 150 kDa), these antibody-based
imaging agents suffer from drawbacks such as long biodistribution
time, poor penetrating capability, and slow clearance from the blood
and normal tissues. EGF, the natural ligand for EGFR, has also been
used to image EGFR expression in vivo [12–15]. Although the size of
EGF (Mw, 6.2 kDa) ismuch smaller compared with those of antibodies,
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it stimulates the EGFR-mediated signaling pathways, which is an un-
wanted property for in vivo imaging [16].
Recently, emerging evidence has indicated that Affibody molecules
could be good candidates as imaging agents. Affibody molecules are a
class of affinity proteins composed of 58 amino acid residues that are
derived from one of the immunoglobulin G (IgG)–binding domains
of staphylococcal protein A. Several successful tumor imaging studies
have been reported using HER2-specific Affibody molecules [17–20].
Affibody molecules binding specifically to EGFR have also been iden-
tified and characterized [21–24].
Owing to the reduced light absorption and scattering of near-infrared
(NIR) light in animal tissues, and the low tissue autofluorescence in the
NIR region,NIR optical imaging offers high sensitivity and signal-to-noise
ratio compared with visible spectrum [25–27]. A variety of molecules
labeled with NIR fluorophores have been successfully used for in vivo
imaging. Some examples include 2-deoxyglucose [28,29], annexinV [30],
RGD [31], EGF [13,14,16,32], and antibodies [7,33,34].
In this study, we evaluated the EGFR-specific Affibody (Eaff ) labeled
with a NIR fluorophore for in vivo optical imaging. The NIR fluoro-
phore labeled EGFR-specific Affibody (Eaff800) was bound specifically
by EGFR-overexpressing A431 cells. In vivo imaging study demonstrated
that Eaff800 accumulated in A431 xenograft tumors, with the highest
tumor-to-background ratio (TBR) achieved 1 day after probe adminis-
tration. Moreover, we examined the specificity of Eaff800 in vivo by
imaging with both Eaff800 and an HER2-specific Affibody labeled with
another NIR fluorophore (Haff682). Results showed that Eaff800 and
Haff682 accumulated inA431 tumor andHER2-overexpressing SKOV3 tu-
mor, respectively. These results demonstrated that NIR fluorophore
labeledAffibodymolecules are promising agents for in vivomolecular imaging.
Materials and Methods
Chemicals and Reagents
The Affibody molecules were provided by Affibody AB (Bromma,
Sweden). The Eaff molecule is in a head-to-tail dimeric form with a
molecular weight of 13.7 kDa.TheHER2-specific Affibody (Haff )mole-
cule is a fusion protein of the HER2monomer with the albumin-binding
domain (ABD) and has a molecular weight of 12.1 kDa. IRDye800CW
maleimide dye (Ex/Em: 774/789 nm) and IRDye800CW-labeled EGF
(EGF800) were from LI-COR Biosciences (Lincoln, NE). TO-PRO-3
and SYTOX Green nucleic acid stain reagents were purchased from
Invitrogen (Carlsbad, CA).DY-682maleimide dye, Recombinant human
EGF and TCEP·HCl was purchased from Dyomics ( Jena, Germany),
R&D Systems (Minneapolis, MN), and Fisher Scientific (Pittsburgh,
PA), respectively.
Conjugation of Affibody Molecules with NIR Dyes
The Affibody used in this study contains a unique C-terminal cys-
teine residue for thiol-reactive maleimide dye labeling. To reduce the
spontaneously formed disulfide bond between the cysteine residues, the
Affibody molecules were incubated with 5 mMTCEP·HCl. The excess
TCEP·HCl was removed by passing the reaction mixture through a
Zeba Spin Desalting Column (Fisher Scientific). The maleimide dye
was reconstituted in DMSO to a concentration of 10 mM and added
to the Affibody solution. The reaction mixture was incubated at room
temperature for 3 hours before passing through another Zeba Spin De-
salting Column to remove free dye. The concentrations of labeled Affi-
body molecules and the labeling efficiency were calculated based on
the absorbance at 280 nm and 778 nm (IRDye800CW) or 688 nm
(DY-682), respectively.
Cell Culture
The human skin epidermoid carcinoma cell line A431, ovarian adeno-
carcinoma cell line SK-OV-3 (SKOV3), and breast adenocarcinoma cell
lines MDA-MB-231 (MDA231) and SK-BR-3 (SKBR3) were obtained
from the American Type Culture Collection (ATCC, Manassas, VA).
A431 and MDA231 cells were maintained in Dulbecco’s modified Ea-
gle medium (DMEM) supplemented with 10% fetal calf serum and
1% penicillin-streptomycin (complete DMEM). SKOV3 and SKBR3
cells were maintained in McCoy 5A medium (McCoy) supplemented
with 10% fetal calf serum and 1% penicillin-streptomycin (com-
plete McCoy).
To collect cell lysates for Western blot analysis, cells were rinsed with
PBS and lysed with radioimmunoprecipitation assay buffer. When treat-
ment with Eaff or EGF was necessary, the agents were diluted in serum-
free medium to the desired concentrations and added to the cells. After
incubation at 37°C for 2 hours, cells were rinsed with PBS and lysed with
radioimmunoprecipitation assay buffer.
Western Blot
The Western blot analysis was performed as previously described
with modifications [35]. In brief, protein samples were denatured by
boiling for 5 minutes and loaded onto 10% Bis-Tris gels. After electro-
phoresis, proteins were transferred to nitrocellulose membranes. Mem-
branes were blocked for 2 hours with Odyssey Blocking Buffer, then
incubated for 1 hour with primary antibodies diluted in Odyssey
Blocking Buffer. The mouse EGFR antibody, mouse P44/42 mitogen-
activated protein kinase (MAPK) (ERK1/2) antibody, rabbit phospho-
EGFR (Tyr1045) antibody, rabbit phospho-P44/42 MAPK (ERK1/2)
antibody, and rabbit HER2/ErbB2 antibody were purchased from Cell
Signaling Technology (Danvers, MA). The mouse pan-Actin antibody
was purchased from NeoMarkers (Fremont, CA). Two primary anti-
bodies from different species (such as mouse anti–P44/42 and rabbit
anti–phospho-P44/42) were added together.
After incubating with primary antibodies, the membranes were
washed with PBS containing 0.1%Tween 20 (PBST) three times. Then
the membranes were incubated for 1 hour with IRDye800CW-
conjugated goat antirabbit IgG and IRDye680-conjugated goat anti-
mouse IgG secondary antibodies (LI-COR Biosciences) diluted in
Odyssey Blocking Buffer. The blots were then washed three times with
PBST and rinsed with PBS. Proteins were visualized by scanning the
membrane on an Odyssey Infrared Imaging System (LI-COR Biosci-
ences) with both 700- and 800-nm channels.
Cell Binding and Uptake Assay
Cells were seeded at approximately 3 × 104 (A431), 2 × 104 (MDA231
and SKBR3), or 1 × 104 (SKOV3) cells per well in 96-well plates and
cultured overnight before the assay. The cell density was approximately
70% to 80% confluent at the time of assay. The NIR f luorophore–
labeled targeting agents were diluted in complete cell culture medium
to designated concentrations and incubated in the 37°C incubator for
2 hours except where otherwise stated. For competition study, unlabeled
agents were diluted in complete medium and incubated with the cells for
1 hour. The competitors were then removed before adding targeting
agents. After incubating with targeting agents, cells were fixed with
3.7% formaldehyde/PBS and washed with PBST. The cells were then
incubated in TO-PRO-3 stain agent (1:5000 in PBS) to normalize for
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cell numbers. After three additional washes with PBST, the plate was
scanned and signal intensity quantified [36].
Microscopic Analysis
Cells were seeded in eight-well chamber slides (Nalge Nunc Inter-
national Corp, Naperville, IL) and cultured overnight. The cells were
incubated with 20 nM targeting agent at 37°C for 2 hours, fixed, and
washed as previously described. Instead of TO-PRO-3, SYTOX
Green nucleic acid stain agent was used to visualize the nuclei by
microscopy. After the final wash, the slides were mounted with
Fluoromount reagent (Sigma, St Louis, MO). The images were ac-
quired using a Leica DM6000b Bio/Med microscope system (Leica
Microsystems, Inc, Bannockburn, IL) equipped with a xenon lamp.
The excitation and emission filters used for NIR imaging are
HQ760/40 and HQ830/50 (Chroma Technology Corp, Rockingham,
VT), respectively. The images were deconvolved using the accompa-
nying software.
Xenograft Mouse Model
All animals were cared for and maintained under the supervision
and guidelines of the University of Nebraska-Lincoln Institutional
Animal Care and Use Committee. Mice were maintained on a puri-
fied maintenance diet (AIN-93M) from Harlan Teklad (Madison,
WI). The xenograft tumors were established as previously described
with modifications [37]. In brief, athymic nude (nu/nu) mice, ob-
tained from Charles River Laboratories, Inc (Cambridge, MA) at
4 weeks of age, were subcutaneously injected with suspension cells
in 0.1 ml of serum-free medium. The numbers of cells injected
was 106 or 5 × 106 for A431 or SKOV3, respectively. To establish
both A431 and SKOV3 tumors on the same mouse, SKOV3 cells
were inoculated 1 week before inoculating A431 cells to achieve sim-
ilar tumor growth.
In Vivo Animal Imaging
Mice were anesthetized with 2% isoflurane throughout the proce-
dures. For imaging experiments, the contrast agent was diluted in
100 μl of PBS and injected through the tail vein. The images were
acquired at the indicated time points with a Pearl Imager (LI-COR
Biosciences). The Ex/Em settings for the 700- and 800-nm channels
were 685/720 and 785/820 nm, respectively. A cooled charge-coupled
device camera was used to collect the images. The images were ana-
lyzed using the accompanying software. Regions of interest (ROIs)
for both tumor and contralateral areas (background) were selected from
equivalent-sized areas containing the same number of pixels. ROIs were
quantified for mean pixel values. TBR was derived by dividing mean
tumor signal by mean background signal [28].
Organ and Tissue Analysis
Mice were killed 1 day after imaging agent injection and dissected
to collect the organs. The excised organs were rinsed in PBS, and
imaged using a Pearl Imager. The organs were then snap-frozen in
OCT compound for cryosectioning. Sections (8-μm thickness) were
scanned on an Odyssey Infrared Imaging System for the targeted
fluorescence signal. To compare the fluorescence signal on tissue sec-
tions, ROIs were drawn on the tissue sections and blank regions of
the slides. The signal intensity was calculated as the average signal
intensity on the tissue region minus the average signal intensity on
the blank region.
Results
The Effect of Eaff on EGFR and ERK1/2 Phosphorylation
It is known that activation of the EGFR tyrosine kinase activity
leads to the phosphorylation of a variety of target proteins, including
ERK1/2 and EGFR itself [38]. To evaluate whether Eaff stimulates
EGFR-mediated signaling pathways, A431 cells were treated with 5
or 20 nM Eaff. In contrast to EGF, which stimulated the phosphory-
lation of both proteins in a dose-dependent manner, Eaff treatment
did not change the phosphorylation level of EGFR and ERK1/2
(p44/p42 MAPK). However, a high concentration of Eaff (100 nM),
when applied together with 5 nM EGF, compromised the stimulatory
effect of EGF on EGFR and ERK1/2 phosphorylation (Figure 1).
Specific Cellular Binding and Uptake of Labeled
Affibody Molecules
Because the Affibody monomer molecule contains five to six lysine
residues [19,39], conjugation of dye molecules to lysine may result in
heterogeneous multiple labeling. It is also possible to disturb the
binding motif by attaching a dye molecule to its internal lysine resi-
dues. To avoid this problem, the Affibody molecules were conjugated
with the maleimide dye to its C-terminal cysteine. The incorporation
of dye into the Affibody molecules was monitored by gel electropho-
resis (Figure W1). The NIR fluorophore–labeled Affibody molecules
were designated as Eaff800 (Eaff labeled with IRDye800CW),
Eaff682 (Eaff labeled with DY-682), Haff800 (Haff labeled with IR-
Dye800CW), and Haff682 (Haff labeled with DY-682), respectively.
Figure 1. The effect of EGF and EGFR-specific Affibody (Eaff) on
EGFR-mediated phosphorylation of EGFR and ERK1/2 (P44/42
MAPK) proteins. A431 cells were treated with either Eaff or EGF.
Two concentrations (5 and 20 nM) for both Eaff (Eaff5 and Eaff20)
and EGF (EGF5 and EGF20) were used. A combination of high-
concentration Eaff (100 nM, Eaff100) and 5 nM EGF was also used
to treat cells. P44/42 MAPK and actin were used as internal con-
trols. The relative expression levels were calculated by dividing the
signal intensities of phospho-EGFR or phospho-P44/P42 by actin
signal intensities. Note that the molecular weight markers in the
second panel (phospho-P44/P42) and the third panel (P44/P42
MAPK) were the same.Ctrl indicates control without drug treatment.
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To compare the protein expression levels of EGFR and HER2 in
various cell lines, cell lysates of MDA231, A431, SKOV3, and SKBR3
cells were analyzed by Western blot. Both EGFR and HER2 proteins
were detected in these cell lines. However, the EGFR level was much
higher in A431 cells than in any other cell lines, whereas HER2 was
highly expressed in SKOV3 and SKBR3 cells (Figure 2A). This finding
was consistent with previous reports on EGFR and HER2 expression
[40]. These cell lines were also used to investigate the binding specificity
of EGFR and HER2-specific Affibody molecules. The binding and up-
take assay was performed by incubating 5 nM Eaff800 or Haff800 with
MDA231, A431, SKOV3, and SKBR3 cells. Results demonstrated that
whereas A431 cells contained high Eaff800 signal, there was only min-
imal Eaff800 binding and uptake for MDA231, SKOV3, or SKBR3
cells. On the contrary, theHER2-specific Haff800 showed the strongest
signal in SKOV3 and SKBR3 cells, and the signal in MDA231 and
A431 cells was low (Figure 2B). On the basis of these results, the A431
cells and SKOV3 cells were selected as EGFR- andHER2-overexpressing
cells, respectively, for subsequent studies.
The binding and uptake of Eaff800 by A431 cells were dependent
on Eaff800 concentration. With the increase of Eaff800 concentration,
the signal intensity also increased (Figure 2C ), with the maximum sig-
nal obtained at approximately 20 to 50 nM. As a comparison, the same
concentrations of Haff800 and free IRDye800CWdye were incubated
with A431 cells at the same condition. The signals from these agents
were minimal, even at a concentration as high as 100 nM (Figure 2C ).
Comparison of Eaff800 with EGF800
NIR fluorophore–labeled EGF has been used as an imaging agent
[13,14]. So it was of interest to compare Eaff and EGF labeled with
the same NIR fluorophore. Both Eaff800 (5 nM) and EGF800 (5 nM)
were diluted in complete DMEM and incubated with A431 cells for
different periods. As shown in Figure 3A, the binding and uptake of
EGF800 was faster than that of Eaff800, and the signal intensity of
EGF800 was higher in the early stage. Before 1 hour, the binding and
uptake of both agents increased over time. At the 1-hour time point,
binding and uptake of EGF800 decreased, whereas the Eaff800 signal
continued to increase. The Eaff800 signal reached its highest level at 4
to 6 hours and declined thereafter (Figure 3A).
Competition analysis was performed by incubating different con-
centrations of unlabeled Eaff or EGF with A431 cells before adding
targeting agents. Both Eaff and EGF blocked the binding and uptake
of Eaff800. The blocking effect of Eaff and EGF was observed at a
concentration as low as 5 nM, which was the same concentration as
Eaff800 used in this assay. With the increase of competitor concen-
trations, the Eaff800 signal declined. However, the competition effect
of Eaff was more prominent than that of EGF, especially at concentra-
tions higher than 20 nM (Figure 3B ). It was also noted that both Eaff
and EGF blocked the binding and uptake of EGF800 by A431 cells
(data not shown).
The localization of Eaff800 and EGF800 in A431 cells were ex-
amined by microscopy. For both Eaff800 and EGF800, intense sig-
nals were associated with the cell membrane. However, foci probably
representative of internalized agents were also observed inside the
cells (Figure 3C ).
Targeting EGFR-Overexpressing Xenograft Tumors
by Eaff800
Eaff800 probewas tested inmouse xenograft tumormodels by in vivo
imaging. Nude mice bearing A431 xenograft tumors were injected with
0.5 nmol of Eaff800 through the tail vain. Whole mouse images were
acquired at different time points after agent administration. Figure 4A
showed a series of these images (dorsal view). Intense signal was found in
the region where the kidney is located. The belly view of the mouse also
revealed high signal intensity at the liver region (data not shown). The
accumulation of Eaff800 signal in the liver and kidney was confirmed
by imaging dissected organs, as discussed later. The tumor could be
identified at 1 hour after probe injection and it becamemost prominent
after 1 day (approximately 24 hours). Quantification of the ROIs of
equivalent-sized areas from the tumor and contralateral region showed
Figure 2. Specific binding and uptake of IRDye800CW-labeled Affi-
body molecules. (A) The protein expression levels of EGFR and
HER2 in MDA-MB-231 (MDA231), A431, SKOV3, and SKBR3 cells.
Actin served as an internal control. The relative expression levels
were calculated by dividing the signal intensities of EGFR or HER2
by actin signal intensities. (B) The binding and uptake of EGFR-
specific Eaff800 and HER2-specific Haff800 by MDA231, A431,
SKOV3, and SKBR3 cells. (C) Concentration-dependent binding and
uptake of Eaff800-, Haff800-, or IRDye800CW-free dye by A431 cells.
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that the signal intensities of both tumor and normal tissue peaked at
20 minutes after agent injection. Thereafter, the signal decreased over
time (Figure 4B ). The signal decline was more dramatic in normal tis-
sues, especially during the period from 6 to 48 hours, resulting in an in-
creasedTBR, which reached the highest level at 24 hours (Figure 4C ). At
96 hours, most of the agent was cleared out of the body. The residual
signals in the tumor and normal tissue were 8.7 ± 0.5% and 5.7 ± 1.0%
of those at the highest levels (20minutes after agent injection), respectively.
To investigate the accumulation of imaging agent in different organs,
mice were killed 1 day after agent injection. The organs were collected
and imaged. Consistent with in vivo imaging observations, signal inten-
sities were high in the liver, kidney, and tumor (Figure 5A ). These or-
gans were then snap-frozen in OCT compound, sectioned at 8-μm
thickness, and scanned. Quantification of tissue section revealed the
strongest signal in the liver, followed by the kidney and tumor. All other
tissues contained only a low level of signal (Figure 5, B and C ). Inter-
estingly, unlike the even distribution of Eaff800 in the liver, a higher
Eaff800 signal was located in the renal cortex of the kidney compared
with other regions (Figure 5B).
Two-color In Vivo Imaging Using Eaff800 and Haff682
Haff conjugated with Alexa Fluor 750 was successfully used for
optical imaging [18]. Before animal injection, Eaff800 andHaff682were
added together to A431 cells or SKOV3 cells to examine whether the
Affibody molecules interfere with each other’s binding. Compared with
the binding and uptake of individual probes, no significant difference
Figure 3. The comparison of cellular binding and uptake between Eaff800 and EGF800. (A) Binding and uptake time course of Eaff800
(5 nM) and EGF800 (5 nM) by A431 cells. (B) The blocking of Eaff800 (5 nM) binding by increasing concentrations of unlabeled Eaff or
EGF. (C) Microscopic examination of Eaff800 (20 nM) and EGF800 (20 nM) binding and uptake by A431 cells. Sytox green was used to
stain the nuclei. Scale bar, 10 μm.
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was observed when two probes were added together (data not shown),
indicating the lack of cross reactivity.
To test the in vivo specificity of labeled Affibody molecules, 100 μl of
imaging agent solution containing 0.5 nmol of Eaff800 and 0.5 nmol
of Haff682 was injected into nude mice bearing both A431 tumors and
SKOV3 tumors through the tail vain. Multiple-color images were ac-
quired 1 day after agent injection. As expected, A431 tumors contained
a higher Eaff800 signal (Figure 6A-a), whereas SKOV3 tumors con-
tained a higher Haff682 signal (Figure 6A-b). The merged picture dis-
played a two-color image representing selective accumulation of two
different probes (Figure 6A-d ). The A431 tumor on the left side is green,
which represented predominant Eaff800 signal, and the SKOV3 tumor
on the right side is red, which represented predominant Haff682 signal.
The TBRs for A431 tumor and SKOV3 tumor were 1.7 ± 0.2 and 2.1 ±
0.3, respectively. Because pseudocolored images can distinguish differ-
ent intensities easier, the mouse images with Eaff800 signal or Haff682
signal were also presented in pseudo color (FigureW2). Images of tumor
sections also demonstrated that Eaff800 andHaff682 accumulated pref-
erably in A431 tumors and SKOV3 tumors, respectively (Figure 6B).
Next, we exchanged the labeling, that is, Eaff was labeled with DY-
682 (Eaff682), andHaff was labeled with IRDye800CW (Haff800). As
expected, Eaff682 accumulated in A431 tumor and Haff800 accu-
mulated in SKOV3 tumor predominantly (Figure W3).
Whereas both probes specifically targeted their respective tumors,
the organ distribution pattern and the clearance rate of Eaff800 and
Haff682 were different. Whole body images showed predominant
Eaff800 signal (green) in the liver region (Figure 6A-d ). The accumu-
lation of Eaff800 in the liver was confirmed by images of dissected
organs (Figure W4A). Analysis of tissue sections revealed that the liver-
to-kidney ratio of Eaff800 signal was approximately 3.8 (Figure W4, B
and C ), which is similar to the result when Eaff800 alone was injected
(liver-to-kidney ratio = 3.5). However, the signal intensities of Haff682
in the liver and kidney were comparable (liver-to-kidney ratio = 1.1;
Figure W4, B and C ). The clearance rate of Eaff800 was faster than
Figure 4. In vivo optical imaging of nude mice bearing A431 tumors using Eaff800. (A) A representative series of whole body images
(dorsal view) acquired at different time points after injection of 0.5 nmol of Eaff800. The tumors were indicated with arrows. (B) Clear-
ance of Eaff800 from the tumor and normal tissue. Average signal intensities were quantified using ROIs of equivalent-sized areas from
the tumor sites and contralateral sites at indicated time points. Data were presented as mean ± SD of three individual mice. (C) TBR at
different time points after probe injection. TBR was calculated by dividing the mean tumor signal by the mean background signal of the
contralateral site.
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that of Haff682. At 1 day after probe administration, the signal in-
tensity of Eaff800 as measured by whole body imaging decreased to
11.1 ± 0.6% of the highest level (20 minutes after agent injection),
whereas residual signal of Haff682 still remained 57.9 ± 1.2% of the
highest level.
When Eaff682 and Haff800 were used, more Eaff682 accumulated
in the liver (Figure W5), revealing that the accumulation of Eaff in the
liver was independent of the f luorophore conjugated.
Discussion
In vivo molecular imaging has become a valuable tool in biomedical
research and drug development [41,42]. The radionuclide-based im-
aging technologies, such as positron emission tomography and single
photon emission computed tomography, have been used in clinical
applications. In the research field, f luorescence optical imaging is be-
coming more and more popular owing to its low cost, ease of use,
longer time window for image capture, and ability to track multiple
probes simultaneously. Compared with the visible spectrum, the NIR
fluorochrome reduces the autofluorescence, maximizes tissue penetra-
tion, and is ideally suitable for noninvasive animal imaging [25,27].
In this study, we labeled the Affibody molecules with organic NIR
fluorescent dyes and characterized these labeled molecules for in vivo
optical imaging. In contrast to some studies in which probes with dif-
ferent labeling (fluorescent dyes or radionuclide) were used for in vitro
cell based assays and in vivo imaging [19,33,39,43], we demonstrated
here that one probe labeled with NIR fluorophore can be used through-
out the study, from plate-based binding and uptake assay, microscopic
analysis, to in vivo animal imaging. Apparently, this will significantly
reduce the working load and cost.
One challenge for molecular imaging is to develop target-specific
imaging agents. A variety of NIR probes labeled with organic dyes or
quantum dots has been developed to track molecular and cellular
Figure 5. Tissue distribution of Eaff800. (A) Nude mice bearing A431 tumors were killed 1 day after Eaff800 injection. The organs were
collected and rinsed in PBS before imaging. Ht indicates heart; In, intestine; Kn, kidney; Ln, lung; Lv, liver; Ms, muscle; Tm, tumor. Note
that the liver was imaged separately and merged to the picture because the liver signal was so strong that it illuminated the surrounding
tissues if imaged together. (B) Fluorescence images of cryosections of dissected organs. The organs were snap-frozen in OCT com-
pound and sectioned at 8-μm thickness. (C) Quantification of signal intensities of tissue sections. Average signal intensities were cal-
culated using ROIs from different tissue sections.
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events in vivo [25,41]. Although these probes have been proven suc-
cessful for in vivo imaging, they are of different origins and function
based on different mechanisms. As a consequence, different strategies
for development and characterization were needed for different targets,
complicating the imaging application. Affibody molecules specific to
different targets can be selected from the same library. Because these
molecules differ from each other by only 13 amino acids [21], the la-
beling and characterization procedure could be standardized, thus
greatly facilitating the development of imaging agents. In this study,
we took advantage of the unique cysteine that is purposely engineered
to the C-terminus of Affibody molecules for maleimide dye conjuga-
tion. This strategy avoided the problem of multiple heterogeneous la-
beling in the case of N -hydroxysuccinimide dye conjugation. As a
result, the labeling was homogeneous and reproducible.
Figure 6. Two-color in vivo optical imaging with Eaff800 and Haff682. (A) Nude mice bearing A431 and SKOV3 tumors on the left and right
sides, respectively, were injected with 100 μl of PBS containing 0.5 nmol of Eaff800 and 0.5 nmol of Haff682. Whole body images (dorsal
view) were acquired 1 day after agent injection. Green and red represent IRDye800CW and DY-682 fluorescence signals, respectively. The
tumors were indicated with arrows. (B) Fluorescence images of cryosections of A431 and SKOV3 tumors. Mice bearing A431 and SKOV3
tumors were killed 1 day after agent injection. The tumors were snap-frozen in OCT compound and sectioned at 8-μm thickness.
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The biologic properties of the labeled Affibody molecules were
evaluated by in vitro cell-based assays. The labeled molecules were
taken up by cells expressing the respective targets (Figure 2B), dem-
onstrating good specificity. Furthermore, no cross-interference was
observed when two Affibody molecules (Eaff800 and Haff682) were
added together. The specificity of Eaff800 was confirmed by the
competition assay. The cellular binding and uptake of Eaff800 by
A431 cells was inhibited by preincubation of unlabeled Eaff or EGF
in a dose-dependent manner (Figure 3B ). The competition between
Eaff and EGF indicated that the binding sites of these two molecules
on EGFR may be close to each other. The occupation of one molecule
to its binding site interferes with the binding of the other molecule. The
competition between Eaff and EGFmay also explain the blocking effect
of Eaff on EGF-stimulated EGFR and ERK1/2 phosphorylation.
An ideal imaging agent should not interfere with the signaling
pathways mediated by the imaging target. Out data showed that Eaff
did not stimulate EGFR-mediated phosphorylation of EGFR and
ERK1/2 proteins (Figure 1). This offers an advantage over EGF, which
is known to stimulate EGFR signaling pathways, resulting in the mod-
ulation of cell proliferation and tumorigenesis [44].
In vivo study showed that Eaff800 was rapidly localized in the
A431 tumor after intravenous injection. Although the tumor was
most clearly visualized after 1 day of probe injection, the tumor loca-
tion could be identified from the background as early as 1 hour and
remained clear after 3 day (Figure 4). This wide time window of
image acquisition provides an advantage over radionuclide probes,
whose image acquisition normally needs to be completed within
hours [10,15,17,19,23]. The stable signal of the fluorescent dye also
makes it suitable for longitudinal monitoring of probe distribution
and clearance over time. It was reported recently that indium 111
(111In)–labeled monomeric EGFR-specific Affibody performed bet-
ter compared with the dimeric form for tumor imaging [24]. It
would be of interest to test whether this is true in the case of NIR
f luorophore labeling.
It has been reported that Affibody molecules labeled with radionu-
clide accumulated in the kidney [19,20,24]. Our results also revealed
that the kidney retained high levels of Haff682 and Eaff800 signals
after 1 day of probe administration (Figure 5). However, the organ
distribution pattern of Eaff800 was different from that of Haff682.
The ratio of liver signal to kidney signal was much higher for Eaff800
compared with that for Haff682, indicating a preferable accumula-
tion of Eaff800 in the liver. This high uptake of Eaff800 by the liver
is independent of the f`luorescent dye conjugated to the Affibody
molecule, as Eaff labeled with DY-682 (Eaff682) also accumulated
preferably in the liver. The high liver uptake is likely due to the specific
binding of Eaff to mouse EGFR, which is expressed in liver cells [45].
This high liver uptake of Eaff800 is in contrast to the observation in the
study using the EGFR-specific Affibody labeled with 111In, in which
kidney was shown to be the prominent organ of radioactivity accumu-
lation [24]. The possible explanation for this discrepancy might be the
labeling difference (fluorescent dye vs radionuclide). However, further
investigation is needed to clarify this point.
Fluorescence optical imaging has the advantage of multiple chan-
nels, which can be used to image two or more targets simultaneously
[7,46]. It has been reported that five different fluorophores were si-
multaneously used to visualize primary draining lymph nodes [47].
Whereas this may be useful for imaging small animals, it will not be
practical for human clinical use. The instruments currently available
for human clinical imaging such as the Zeiss Pentero as well as in-
struments currently under development are focused on using wave-
lengths solely in the NIR region between 700 and 850 nm. In the
current study, we labeled EGFR- or HER2-specific Affibody mole-
cules with two NIR f luorophores, respectively. The specific uptake of
the two probes by EGFR- or HER2-overexpressing tumors was re-
vealed by two-color imaging (Figure 6). It was noted that low levels
of Eaff800 and Haff682 signals were also detected in SKOV3 tumor
and A431 tumor, respectively. This undesirable signal might be
caused by the binding of Eaff800 and Haff682 to low levels of EGFR
in SKOV3 and HER2 in A431, respectively. Nonspecific binding of
probes might also contribute to this nontargeted tumor accumulation.
In principle, this two-color imaging method can be applied to detect
and differentiate any types of tumors that overexpress unique cell mar-
kers. It is worth noting that the tumors in the two-color imaging exper-
iment were smaller than those used in other similar studies. The mean
tumor weights were 13.3 ± 5.9 and 11.8 ± 2.1 mg for A431 and
SKOV3 tumors, respectively. As a comparison, the tumor weights in
other studies were between 100 and 300 mg [18,48]. These results
demonstrated the capability of Eaff800 and Haff682 to identify small
tumors at early stages.
It has been known that fusion of ABD to imaging probes could
prolong the circulation half-life of the probes [43]. The ABD effect
might account for the slow clearance of Haff800, which contains an
N-terminal ABD [49]. Studies also demonstrated that fusion of an
ABD to an HER2-specific Affibody improved the performance of
the Affibody as an optical imaging agent [18]. It would be interesting
to see whether the same strategy can be applied to the Eaff molecule
to further improve its performance.
In conclusion, we reported here the development and characteriza-
tion of an optical imaging agent Eaff800. This agent was based on an
Affibody molecule specifically binding to EGFR and labeled with a
NIR fluorophore. The specificity of Eaff800 was examined by in vitro
cell binding and uptake analysis and confirmed by targeting EGFR-
overexpressing tumors in xenograft mouse models. Moreover, in com-
bination with an HER2-specific probe Haff682, Eaff800 could be used
to distinguish between EGFR- and HER2-overexpressing tumors.
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Figure W1. Gel image of Affibody molecules labeled with IR-
Dye800CW or DY-682. Labeled Affibody molecules were purified
by passing reaction mixture through a Zeba Spin Desalting Column.
Purified samples (0.2 pmol each) were separated on a Bis-Tris gel.
Figure W2. Pseudocolored images of mouse with Eaff800 signal
(A) or Haff682 signal (B). Note that S2A and S2B were pseudoco-
lored images of Figure 6, A-a and A-b, respectively. See Figure 6
for details of experiment.
Figure W3. Two-color in vivo optical imaging with Eaff682 and
Haff800. Nude mice bearing A431 and SKOV3 tumors on the left
and right sides, respectively, were injected with 100 μl of PBS con-
taining 0.5 nmol of Eaff682 and 0.5 nmol of Haff800. Whole body
images (dorsal view) were acquired 1 day after agent injection.
Green and red represent IRDye800CW and DY-682 fluorescence
signals, respectively. The tumors are indicated with arrows.
Figure W4. Accumulation of Eaff800 and Haff682 in mouse liver and kidney. (A) Images of the liver and kidney. Mice were killed 1 day
after imaging agent injection. The organs were collected and rinsed in PBS before imaging. Green and red represent IRDye800CW and
DY-682 fluorescence signals, respectively. Kn indicates kidney; Lv, liver. (B) Sections of mouse liver and kidney. The organs were snap-
frozen in OCT compound and sectioned at 8-μm thickness. (C) Liver-to-kidney ratio of Eaff800 and Haff682 signal intensities. Average
signal intensities were calculated using ROIs with the same sizes from different tissue sections. Liver-to-kidney ratio was calculated by
dividing liver signal intensity by kidney signal intensity.
Figure W5. Accumulation of Eaff682 and Haff800 in mouse liver
and kidney. Mice were killed 1 day after imaging agent injection.
The liver and kidney were collected and rinsed in PBS before im-
aging. Green and red represent IRDye800CW and DY-682 fluores-
cence signals, respectively. Note the predominant Eaff682 signal
in the liver. Kn indicates kidney; Lv, liver.
